Singapore markets closed

GILD Jun 2024 69.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.1800+0.1300 (+260.00%)
As of 03:24PM EDT. Market open.
Full screen
Previous close0.0500
Open0.1600
Bid0.1200
Ask0.3500
Strike69.00
Expiry date2024-06-28
Day's range0.1600 - 0.2200
Contract rangeN/A
Volume78
Open interest81
  • Barrons.com

    Gilead Stock Gains. It’s Trying to Get Into the Obesity Drug Game.

    Gilead Sciences stock was climbing Friday on hopes that it would get into the obesity-drug game. GLP-1s, the technical name for the popular obesity drugs, has been one of the biggest drivers of pharmaceutical stocks in recent months. Which may be why Gilead stock has gained 2.8% to $64.55 in afternoon trading Friday after Jefferies released a note late Thursday night.

  • GuruFocus.com

    Gilead Sciences Inc's Dividend Analysis

    Gilead Sciences Inc (NASDAQ:GILD) recently announced a dividend of $0.77 per share, payable on 2024-06-27, with the ex-dividend date set for 2024-06-14. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into Gilead Sciences Inc's dividend performance and assess its sustainability.

  • Business Wire

    New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment

    SANTA MONICA, Calif., June 14, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced results from three new analyses for Yescarta® (axicabtagene ciloleucel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL), including both new clinical research and real-world evidence highlighting manufacturing and product characteristics of Yescarta, and outpatient administration of both Yescarta and Tecartus® (brexucabtagene autoleucel) at the 2024 European Hematology Association (EHA) Annual Co